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Abstract 
Lymphatic filariasis is a mosquito borne parasitic infection that cause severe economic burden in several parts of the 
world. Currently there is no vaccine available to prevent this infection in human. Multidrug therapy is effective, 
however, requires annual treatment and there is significant concern of drug resistance. In this manuscript we 
describe development of a multivalent DNA based vaccine comprising BmALT-2 and BmHSP antigens of 
lymphatic filariasis. Challenge experiments using third stage infective larvae of Brugia malayi in a mouse model 
suggested that nearly 90% protection can be achieved using the multivalent formulation in a DNA prime protein 
boost approach. The vaccination regimen induced significant IgG antibody responses and ELISPOT analysis for 
secreted cytokines from the spleen cells of vaccinated animals showed that these cells produce significant amount of 
IL-4. Results from this study thus show that a multivalent vaccine formulation of BmALT-2 and BmHSP is an 
excellent vaccine for lymphatic filariasis and significant protection can be achieved against a challenge infection 
with B. malayi in a mouse model. 
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1. Introduction 
Lymphatic filariasis caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi, and Brugia timori, 
affects more than 120 million people worldwide [1]. Mass drug administration program by the World Health 
Organization, is significantly reducing the incidence rate of lymphatic filariasis in many parts of the world [2]. 
Nevertheless, lack of effectiveness to the mass drug administration has been reported from several endemic regions 
mainly due to noncompliance [3, 4]. In addition, drug resistance has been reported to at least one of the drugs in the 
mass drug combination [5, 6]. Since yearly administration of the mass drugs is required for effective control, there is 
an alarming concern for selecting drug resistant parasites. Therefore, there is an immediate need for a multipronged 
approach in controlling this mosquito borne infection. Combining vaccination with chemotherapy is an excellent 
strategy for controlling this infection, especially to achieve the targeted elimination date of 2020 by the Global 
Programme for Elimination of Lymphatic Filariasis [7]. Unfortunately, there are no effective vaccines currently 
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available to control this infection. Several subunit candidate vaccine antigens have been tested in laboratory animals 
with variable results [8-14]. Lymphatic filariasis is a multicellular organism with complex life cycle and produce 
large array of host modulatory molecules. Thus, fighting against this infection with a single antigen vaccine can be 
difficult. By screening a phage display cDNA expression library of the B. malayi parasite with sera from immune 
individuals, we identified several potential vaccine candidates [15]. Varying degree of protection was achieved with 
each of the candidate vaccine antigens when given as a DNA, protein or prime boost vaccine [14]. Therefore, in this 
study, we selected the two most promising candidate antigens, Brugia malayi Abundant larval transcript-2 
(BmALT-2) and B. malayi small heat shock protein (BmHSP) for further development as a multivalent vaccine. We 
also compared the efficacy of the vaccine when given as a monovalent formulation or as a multivalent formulation. 
Previous studies showed that a DNA prime protein boost gave maximum protection. Therefore, in this study we 
used a prime boost approach to evaluate the multivalent vaccine formulation.     
 
2. Materials and methods: 
Parasite:
Brugia malayi L3s were obtained from the NIAID/NIH Filariasis Research Reagent Resource Center (FR3) at the 
University of Georgia, Athens, GA. 
 
Construction of monovalent and multivalent DNA vaccines: 
Monovalent DNA vaccine consisted of Bmhsp or Bmalt-2 in pVAX1 vector. To prepare the monovalent vaccine, 
codon optimized Bmhsp or Bmalt-2 genes were cloned into the eukaryotic expression vector pVAX1 (Invitrogen, 
Carlsbad, CA) using insert specific primers [15]. The multivalent vaccine consisted of Bmhsp and Bmalt-2 genes in 
the same pVAX1 vector. Codon optimized Bmhsp gene was first cloned into pVAX1 vector with no stop codon in 
the reverse primer (5’-CCGGAATTCTCACTTGTCGTTGGTG-3’) but contained a pst I site. Codon optimized 
Bmalt-2 gene was then inserted into this clone using gene specific primers [15]. PCR parameters for all the three 
constructs were: 94°C denaturation for 30 s, 50°C primer annealing for 30 s, 72°C primer extension for 30 s for 
30 cycles; a final extension of 5 min was performed at 72° C. Insert DNA was finally sequenced to ensure 
authenticity of the cloned nucleotide sequence on both strands. Plasmids were maintained and propagated in E.coli 
Top10Fc cells. Plasmids were purified using endotoxin free plasmid extraction kit (Qiagen, Valencia, CA). DNA 
was analyzed by agarose gel electrophoresis and quantified in a spectrophotometer (OD 260/280, ratio>1.8). 
 
Expression and purification of recombinant proteins: All the genes were cloned in pRSET-A vector (with an N-
terminal hexahistidine tag) to produce recombinant proteins. Bmhsp and Bmalt-2 constructs were transformed into 
BL21(DE3) containing pLysS E.coli host (Invitrogen) to minimize toxicity due to the protein. When absorbance of 
the cultures reached 0.6 OD value, 1mM of IPTG (isopropyl thio-d-galacto pyranoside) was added to the cultures 
and incubated for an additional 3 hours to induce the gene expression. After lysing the cells, total proteins were 
separated in 15% and 12% SDS-PAGE to confirm the expression of his-tag recombinant BmHSP (rBmHSP) and 
rBmALT-2 proteins. The recombinant proteins were then purified using an immobilized cobalt metal affinity 
column chromatography (Clontech, Mountain View, CA) as per the manufacturer’s recommendations. Recombinant 
proteins were then separated in SDS-PAGE and stained with coomassie brilliant blue R250 and silver stain. These 
studies showed that a single band was obtained after column purification (data not shown). Endotoxins if any in the 
recombinant preparations were removed by passing the recombinant proteins through polymyxin B affinity columns 
(Thermo Fisher Scientific, Rockford, IL) and the levels of endotoxin in the final preparations were determined using 
an E-TOXATE kit (Sigma, St Louis, MO) as per manufacturer’s instructions. Endotoxin levels were below detection 
limits in these recombinant protein preparations (data not shown). 
 
Immunization of mice:
Six-weeks old male Balb/c mice purchased from Charles River Laboratories were used in these experiments. 
Humane use of animals in this study and the protocol was approved by the IACUC committee at the College of 
Medicine, University of Illinois Rockford. Mice were divided into four (4) groups of five (5) animals each. All mice 
were immunized subcutaneously using a DNA prime - protein boost vaccine regimen. All experimental groups of 
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mice were primed with two injections of endotoxin free codon optimized DNA given in 50 Pl volume and boosted 
with two doses of recombinant proteins suspended in alum (50 Pl each) given at two weeks interval. 
 
Group A mice were primed with 100ȝg of pVAXBmhsp and boosted with 15ȝg of rBmHSP; Group B mice were 
primed with 100ȝg of pVAX Bmalt-2 and boosted with 15 Pg of rBmALT-2; Group C mice were primed with 
100ȝg of pVAXBmhsp/Bmalt-2 DNA and boosted with 15 Pg of rBmHSP and 15 Pg of rBmALT-2. Group D mice 
received 100 Pg of pVAX1 vector plus 50ȝl of alum and served as controls. Blood samples were collected from 
each mouse before immunization and one month after the last booster dose. Sera were separated and stored at -800C. 
 
Evaluation of antibody responses in mice: 
Levels of anti-BmHSP and anti-BmALT-2 antibodies were measured in the sera of immunized and control groups of 
mice using an indirect ELISA as described previously [14, 15].  Briefly, wells of 96 well microtitre plates were 
coated with rBmHSP, rBmALT-2 or rBmHSP (1 ȝg/ml) in carbonate buffer (pH 9.6) overnight at 4°C. After 
washing the wells unbound sites were blocked with 3% BSA for 1 h at 37°C. Diluted sera samples were then added 
to the wells and incubated further overnight at 4°C. After washing the wells, HRP labelled rabbit anti-mouse IgG 
was added (1:5000) and incubated further for 1 hr at 37°C.  Color was developed using ABTS [2, 2´-azinobis (3-
ethylbenzothiazoline-6-sulfonic acid)] substrate. Absorbance was measured at 405 nm in a microplate reader (Bio-
Rad, Hercules, CA).
   
Protection studies in mice: 
Vaccine potential of the monovalent and multivalent vaccine formulations were then evaluated in a mice model. 
Mice were immunized as described above using the prime boost approach. Vector plus alum group served as 
negative controls. Immunized and control animals were challenged using a micropore chamber method as described 
by [16]. Briefly, micropore chambers were assembled using 14 x 2 mm plexi rings (Millipore Corporations, 
Bedford, MA) and 5.0 Pm nucleopore polycarbonate membranes (Millipore Corporations) that were attached to the 
plexi glass rings with cynoacrylic adhesive and dental cement. The chambers were immersed overnight at 370C in 
sterile RPMI medium containing gentamycin and antimycotic solution. Before challenge experiments, 20 live 
infective L3s suspended in RPMI1640 medium supplemented with 15% heat inactivated fetal calf serum (FCS), 
were introduced into the micropore chambers and the opening was sealed with dental cement. Micropore chamber 
containing the L3s were then surgically implanted into the peritoneal cavity of each mice under anaesthesia. Aseptic 
conditions were followed for the surgical procedures. After 48 h of implantation, animals were sacrificed and the 
chambers were recovered from peritoneal cavity. Contents of each chamber were emptied and larvae were examined 
microscopically for adherence of cells and for larval death. Larval viability was determined microscopically at 100 
x. The percentage of protection was expressed as the number of dead parasites y number of total parasites recovered 
x 100. 
 
Cytokine analysis in mice: 
The percent of rBmHSP and rBmALT-2 specific interferon-Ȗ (IFN-Ȗ) and interleukin-4 (IL-4) secreting cells were 
determined in the spleen of control and vaccinated mice using an ELISPOT assay. Briefly, Millipore MultiScreen 
HTS Filter plates were coated with monoclonal rat anti mouse IFN-Ȗ or monoclonal rat anti-mouse IL-4 antibodies 
(BD Pharmigen, San Diego, CA) at a concentration of 10 ȝg/ml in PBS buffer. After washing the plates, non-
specific sites were blocked by incubating the wells in complete RPMI with 10% foetal calf serum for one hour at 
room temperature. Approximately 3 x 106 spleen cells suspended in complete RPMI1640 medium supplemented 
with 10% heat inactivated FBS were then added to each wells. Cells were stimulated with rBmHSP or rBmALT-2 
(1ȝg/ml). Unstimulated cells served as controls. 48 hours after incubation at 37 °C in humidified 5% CO2, plates 
were washed and further incubated for 1 hour at room temperature with 2μg of biotinylated rat anti mouse IFN-Ȗ or 
biotinylated rat anti mouse IL-4 antibody (BD Pharmigen). After washing the plates, streptavidin conjugated horse 
radish peroxidase (Thermo Fisher Scientific) was added (1:800) to each well and incubated at room temperature for 
one hour. Plates were washed and colour developed using DAB substrate (Thermo Fisher Scientific). Total numbers 
of spots were counted under a dissection microscope. 
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Statistical Analysis:  
Statistical analysis was performed using XL STAT software v.7.5.2 (Kovach Computing Services, Anglesey, UK). 
Statistical significance between comparable groups was estimated using appropriate non-parametric tests, with the 
level of significance set at p<0.05.                                                                                   
 
Results and Discussion: 
Antibody responses in mice: 
One of the first questions we asked was does the multivalent vaccine elicit significant antibodies against each of the 
antigenic components. Previous studies from our laboratory showed that mice similarly vaccinated with B. malayi 
antigens elicited significant host protective IgG antibodies [14]. Therefore, in this study, we focused only in 
measuring IgG antibody titres. As expected, the monovalent immunization with Bmhsp + rBmHSP and Bmalt-2 + 
rBmALT-2 did elicit significant (p< 0.005) titres of anti-BmHSp and anti-BmALT-2 IgG antibodies (Figure 1). The 
multivalent vaccine also elicited significant IgG antibody titres. Following multivalent vaccine the mice produced 
IgG antibodies against both BmHSP and BmALT-2 equally suggesting that the antigens do not interfere or compete 
for dominance. An interesting finding was that the multivalent vaccine elicited 1.5 to 1.75 fold higher (p< 0.005) 
titres of IgG antibodies compared to the monovalent vaccine (Figure 1). These finding suggested that the two 
antigens in the multivalent formulation can act synergistically by increasing the vaccine-induced antibody responses 
against each antigens in the vaccinated mice. The findings also suggested that combining these two antigens in the 
vaccine formulation has a great advantage. Given the robust IgG antibody responses induced following vaccination, 
it is also possible that the concentration of the component antigens in the multivalent preparation can be reduced. 





Figure 1. Titer of anti-BmHSP and anti-BmALT-2 IgG antibodies in the sera of vaccinated mice. 6-week-old balb/c mice were 
immunized using a prime boost approach with a monovalent vaccine (Bmhsp prime and rBmHSP boost or Bmalt-2 prime and 
rBmALT-2 boost) and multivalent vaccine (Bmhsp/Bmalt-2 prime and rBmHSP and rBmALT-2 boost). Titer of IgG antibodies 
were measured in the sera using an indirect ELISA. Data presented here is the antibody titer 2 weeks after the last booster. 
Results show that both bivalent and multivalent vaccines induce significant IgG antibodies against each of the component 
Vaccination groups  
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antigens. The findings also show that the antigens in the monovalent and multivalent formulations act synergistically in boosting 
the immune responses. N=5. Statistically significant ** p <0.001, * p < 0.05. Values represented are mean + SD. 
Multivalent vaccine induces significant protection in mice:
Above results show that significant IgG antibodies are elicited following vaccination with monovalent and 
multivalent vaccine preparations. To test if the immune responses elicited following vaccination is protective, we 
challenged vaccinated animals with live third stage infective larvae (L3) of B. malayi. Since the parasites do not 
reach to maturity in these animals, a better recovery of worms is obtained if the parasites are surgically implanted 
into the animals. We used a standard micropore chamber challenge method as described previously by [16]. These 
studies showed that close to 61% protection can be achieved in mice immunized with a monovalent vaccine (Table 
1). This is highly significant (p <0.001) compared to negative controls. This finding also shows that rBmHSP and 
rBmALT-2 are promising vaccine candidates for lymphatic filariasis. Challenge experiments in mice immunized 
with multivalent vaccine showed that significantly (p <0.005) higher protection can be achieved compared to 
monovalent vaccination (Table 1). These findings also clearly correlated with the higher IgG antibody titre in these 
animals and support the above finding that rBmALT-2 and rBmHSP can synergistically enhance the protective 
immune responses in vaccinated animals when given as a prime boost regimen (Table 1). 
Table 1. Percent protection in vaccinated mice after a challenge infection. 
 
Vaccination regimen Percent Larval deatha Groups 
Bmhsp DNA prime and rBmHSP protein boost       61 ±  4.24 Monovalent 
Bmalt-2 DNA prime and rBmALT-2 protein boost       76 ± 8.21 Monovalent 
Bmhsp+Bmalt-2 prime and rBmHSP and rBmALT-
2 protein boost 
       
      90 ± 7.53 
Multivalent 
pVAX plus alum control        22 ± 10.41 Control 
 




We then evaluated the immunological characteristics of the protective responses in vaccinated mice by evaluating 
the secreted cytokine responses of spleen cells in response to the vaccine antigens. When spleen cells were 
stimulated with rBmHSP or rBmALT there was significant antigen-specific proliferation of spleen cells (data not 
shown) suggesting a strong recall cellular response to the antigens. To identify the cytokine profile of these antigen-
responding cells, we counted the IFN-J and IL-4 secreting cells using an ELISPOT assay. Results from these studies 
showed that spleen cells from mice vaccinated with multivalent vaccine were predominantly secreting IL-4 (Figure 
2). The numbers of IFN-J secreting cells were very low. Overall, these findings suggested that vaccine-induced 
protection is largely mediated by Th2 type responses. 
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Figure 2.  Number of IL-4 (A) and IFN-Ȗ (B) secreting cells were measured in the spleen of mice vaccinated with monovalent 
(BmHSP or BmALT-2) or multivalent vaccine. An ELISPOT assay was performed after stimulating the cells with rBmHSP or 
rBmALT (1 Pg/ml). Single cell preparations of spleen cells were stimulated with respective antigens for 48 hours and spot 
forming cells were counted. Results show that both monovalent and multivalent vaccine promoted IL-4 secreting cells. 
Multivalent vaccination induced the higher number of IL-4 producing cells than controls. IFN-J producing cells were 
comparatively low. These findings further confirm that BmHSP and BmALT-2 synergistically boost the immune responses in 
vaccinated animals following a multivalent vaccination. N=5. Results are expressed as mean number of spot forming units per 3 
x 106 cells ± SD. 
 
 
In conclusion, results presented in the study show that a multivalent vaccine formulation consisting of BmHSP and 
BmALT-2 is an excellent vaccine against lymphatic filariasis. The studies also showed that a DNA prime protein 
boost regimen is more robust in eliciting the protective immune responses. Finally, the vaccine-induced protection 





This study was funded by an NIH RO1 grant (AI064745). We would also like to thank NIAID/NIH Filariasis 
Research Reagent Resource Center (FR3) at the University of Georgia, Athens, GA for providing us with parasite 





[1] WHO. Lymphatic filariasis: the disease and its control. Fifth report of the WHO Expert Committee on 
Filariasis. World Health Organ Tech Rep Ser 1992;821:1-71. 
[2] Hotez PJ. Mass drug administration and integrated control for the world's high-prevalence neglected 
tropical diseases. Clin Pharmacol Ther 2009 Jun;85(6):659-64. 
[3] Babu BV, Mishra S. Mass drug administration under the programme to eliminate lymphatic filariasis in 
Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance. 
Trans R Soc Trop Med Hyg 2008 Dec;102(12):1207-13. 
A
B
18  A. Samykutty et al. / Procedia in Vaccinology 3 (2010) 12–18
[4] El-Setouhy M, Abd Elaziz KM, Helmy H, Farid HA, Kamal HA, Ramzy RM, et al. The effect of 
compliance on the impact of mass drug administration for elimination of lymphatic filariasis in Egypt. Am 
J Trop Med Hyg 2007 Dec;77(6):1069-73. 
[5] Horton J. The development of albendazole for lymphatic filariasis. Ann Trop Med Parasitol 
2009;103(1):S33-40. 
[6] Schwab AE, Churcher TS, Schwab AJ, Basanez MG, Prichard RK. An analysis of the population genetics 
of potential multi-drug resistance in Wuchereria bancrofti due to combination chemotherapy. Parasitology 
2007 Jul;134(Pt 7):1025-40. 
[7] Molyneux DH. Filaria control and elimination: diagnostic, monitoring and surveillance needs. Trans R Soc 
Trop Med Hyg 2009 Apr;103(4):338-41. 
[8] Bottazzi ME, Miles AP, Diemert D, Hotez PJ. An ounce of prevention on a budget: a nonprofit approach to 
developing vaccines against neglected diseases. Expert Rev Vaccines 2006 Apr;5(2):189-98. 
[9] Chenthamarakshan V, Reddy MV, Harinath BC. Immunoprophylactic potential of a 120 kDa Brugia 
malayi adult antigen fraction, BmA-2, in lymphatic filariasis. Parasite Immunol 1995 Jun;17(6):277-85. 
[10] Dissanayake S, Perler FB, Xu M, Southworth MW, Yee CK, Wang S, et al. Differential recognition of 
microfilarial chitinase, a transmission-blocking vaccine candidate antigen, by sera from patients with 
Brugian and Bancroftian filariasis. Am J Trop Med Hyg 1995 Sep;53(3):289-94. 
[11] Li BW, Chandrashekar R, Weil GJ. Vaccination with recombinant filarial paramyosin induces partial 
immunity to Brugia malayi infection in jirds. J Immunol 1993 Mar 1;150(5):1881-5. 
[12] Maizels RM, Gomez-Escobar N, Gregory WF, Murray J, Zang X. Immune evasion genes from filarial 
nematodes. Int J Parasitol 2001 Jul;31(9):889-98. 
[13] Thirugnanam S, Pandiaraja P, Ramaswamy K, Murugan V, Gnanasekar M, Nandakumar K, et al. Brugia 
malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 
protein and prime-boost vaccine regimens in a jird model. Exp Parasitol 2007 Aug;116(4):483-91. 
[14] Veerapathran A, Dakshinamoorthy G, Gnanasekar M, Reddy MV, Kalyanasundaram R. Evaluation of 
Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis. PLoS Negl Trop Dis 
2009;3(6):e457. 
[15] Gnanasekar M, Rao KV, He YX, Mishra PK, Nutman TB, Kaliraj P, et al. Novel phage display-based 
subtractive screening to identify vaccine candidates of Brugia malayi. Infect Immun 2004 Aug;72(8):4707-
15. 
[16] Abraham D, Grieve RB, Holy JM, Christensen BM. Immunity to larval Brugia malayi in BALB/c mice: 
protective immunity and inhibition of larval development. Am J Trop Med Hyg 1989 Jun;40(6):598-604. 
 
 
 
 
 
 
